5. Nektar Therapeutics ( NKTR) is a clinical-stage biopharmaceutical major.

The company reported a loss of 24 cents per share for 2010 fourth quarter against a loss of 8 cents and 9 cents per share in the year-ago and quarter-ago periods, respectively. Loss per share is pegged at $1.31 for 2011 and $1.16 cents for 2012.

The stock has a 73% upside over the next 12 months with a consensus target price of $15.4, analysts polled by Bloomberg forecast. In comparison, pharma giants Johnson & Johnson ( JNJ), Pfizer ( PFE), Merck ( MRK), Abbott Laboratories ( ABT), Bristol Myers Squibb ( BMY) and Eli Lilly ( LLY) have upsides of 1%-16%.

Of the 11 analysts covering the stock, 8 recommend buying and 3 suggest holding, representing 73% buy ratings.

If you liked this article you might like

China Real Estate Information Corporation Stock Downgraded (CRIC)

China Real Estate Information Corporation Stock Downgraded (CRIC)

3 Stocks That Will Lead Next China Rally

3 Stocks That Will Lead Next China Rally

China Real Estate Information Corporation Stock Upgraded (CRIC)

China Real Estate Information Corporation Stock Upgraded (CRIC)

China Real Estate Information Corporation Stock Downgraded By TheStreet Ratings (CRIC)

China Real Estate Information Corporation Stock Downgraded By TheStreet Ratings (CRIC)

Don Dion's Weekly ETF Winners and Losers

Don Dion's Weekly ETF Winners and Losers